Policy Brief: Unlocking Affordable, At-Home Relief for Overactive Bladder

Executive Summary

Over 33 million Americans suffer from Overactive Bladder (OAB). Although therapy ranges from pills, pads, and exercise to electrical stimulation and surgery, most patients and providers overlook a proven, low-cost, at-home treatment option: Transcutaneous Tibial Nerve Stimulation (TTNS). It is not experimental. Europeans, Australians, and others outside the United States have used it for over 10 years. I have controlled my OAB symptoms successfully with PTNS and TTNS.

Despite evidence of equal or superior efficacy—especially given it is non-invasive, low-cost, and self-administered—TTNS remains largely ignored in American clinical practice. This oversight imposes unnecessary costs and reduces access and convenience for patients, especially in rural and underinsured populations. It also increases healthcare workload.

Public health policy, insurance guidelines, and clinical protocols must urgently recognize TTNS as a viable, accessible first-line intervention for OAB care. Perhaps most difficult, the mindset of urologists and their office operations must incorporate significant change and consider TTNS.

The Issue: High-Cost, Professional Care Or a Low-Cost, At-Home Alternative –

• Both PTNS and TTNS are 30-minute electrical Tibial nerve stimulation treatments that begin weekly for 12 weeks and continue monthly. The amount of electricity actually reaching the nerve and the associated discomfort is the same for both treatments.

• PTNS: Annual cost is $2,000-$3,000 or more. Treatments require scheduling, travel to a clinic, and acupuncture needle-nerve contact for the electrical stimulation to be effective

• TTNS: The cost is about $1 per session using a TENS (Transcutaneous Electrical Nerve Stimulation)device (~$50). Treatments are non-invasive and conveniently self-administered at home, with electricity delivered to the nerve via a skin pad.
• For over two years, my TTNS results have been 100% reliable. My PTNS was reliable until a nurse failed to move the needle to achieve the required needle-nerve contact.
• Rural and underserved patients have limited access to PTNS, whereas TTNS offers a much more convenient and less costly home-based solution.

Clinical Evidence

• NIH (2022): TTNS outcomes equivalent to PTNS; further studies recommended [1]
• Brinkhaus et al. (2017): TTNS is non-inferior to PTNS.
• TTNS avoids the variability associated with the PTNS needle-nerve connection.

Barriers to Adoption

• Regulatory Gap: TTNS lacks explicit FDA approval for the treatment of OAB.
• Reimbursement Block: Medicare and private insurers do not cover TTNS.
• Provider Awareness and Buy-In: U.S.-based Urologists rarely, if ever, offer TTNS. – Patient self-administration of TTNS will reduce Urologists’ and clinic revenue from PTNS and other, even more expensive alternative treatments. Unlocking the patient benefits of TTNS will require a comprehensive initiative to change U.S. attitudes and established U.S. practices.

Comparative Cost & Access Matrix

Treatment	Cost	Access	Reimbursed
PTNS	$2,000-$3,000/year or more	Low (in-office)	Partial
TTNS	~$50[2]	High (at-home)	No
Medications	$300-$1,200/year	Moderate	Partial
Implants	$15,000+[3]	Low	Partial

Even a modest TTNS uptake could save Medicare over $300 million annually. Insured patients may save significant costs by avoiding professional treatment copays and ongoing travel while improving convenience and enhancing treatment reliability.

Policy Recommendations

1. Fund NIH/NIDDK pilot programs to track uptake and cost savings.
2. Accelerate FDA clearance for TTNS using TENS devices.
3. Include TTNS under Medicare CPT codes for neuromodulation.
4. Update clinical guidelines (AUA, ACOG) to include TTNS as a front-line therapy.
5. Launch education campaigns through NAFC, AUA, ACOG, and health networks to ensure knowledgeable patients and to incorporate TTNS into the treatments U.S. urologists offer.

Call to Action  

I am seeking an organization to take ownership of my domain, OABTherapy101.org, to create a comprehensive educational platform on alternative OAB treatments, and to support the national education campaign. This site would improve patient access to evidence-based resources and knowledge, strengthening the organization’s reputation for patient advocacy and digital health education.

TTNS may not offer relief for every patient with OAB symptoms. Still, its efficacy and patient-friendly design deserve far greater clinical recognition in the U.S. Ignoring TTNS is not only medically negligent but unfair. It leaves patients navigating costly, inconvenient, potentially less effective treatments or abandoning care altogether. We urge health leaders to address this imbalance, adopt TTNS as a proven, patient-centered solution, and revise outdated policies to ensure accessible and affordable relief for millions of patients. 

Contact   Louis Muench, OAB Patient & Advocate, LBMuench@Gmail.com, 248 563-6453 

[1] I would not know about TTNS if not for this study, which I can no longer find on the web. 

[2] The price of my TENS device is $50. Pads are reusable and cost less than $1 per treatment. The main difference between my TENS electrical stimulation device and PTNS devices made by either Laborie or Medtronic is its ability to deliver 105 mA of current, compared with the maximum of 9 mA for PTNS devices. Nurses or patients set PTNS and TTNS currents to a level of discomfort that is relatively minor, not counting the minutes until treatment completion. All PTNS current stimulates the Tibial nerve. For TTNS, some electric current passes through flesh without stimulating the Tibial nerve, but the portion of the TENS current that passes through the Tibial nerve creates the same patient discomfort and is sufficient to achieve the same result.

[3] An implant can be substantially more. An Interstim device can cost $30,000, and the total bill can reach $70,000, including doctor and hospital fees, according to an online report.